Chronic myeloid leukemia (CML)
- Phase 1
- Phase 2
- Phase 3
With the use of gene-editing technology
Changing the function of the cell to decrease chances of illness and to save human lives
Advances in synthetic biology enable us to correct errors that cause disease using CRISPR/Cas gene editing technology
We focus in the fields of immuno-oncology with potentials for other genetic disorders
*Depending on gene of interest
Our improvement of the CRISPR system offers new therapeutic and cell-editing opportunities.
LABIOTECH.eu named CRISPR as one of the four technologies that will change cancer treatment.Clara Rodriguez Fernandez
The core of our strategy is to couple Cas9 to the exonuclease to promote deletions at the specific target genomic site that prevents the repair of non-modified DNA. The best efficiency is achieved by using noncovalent coupling through coiled-coil dimers, developed previously by the Jerala group. Improved efficiency of target gene inactivation is one of the key applications of CRISPR, such as targeting dominant pathogenic mutations in primary cells for therapy or biotechnological applications. This is reflected in our portfolio and applications, notably immune-oncology conditions where we focused our interest.
One of the main inventors, dr. Duško Lainšček
CCEdit continues the mission to advance biotechnology innovation and translation into the clinic, and foster entrepreneurship in Slovenia. For this, we recently hosted Jernej Godec, Ph.D. a Senior Associate at Atlas Venture. Atlas Venture is a Cambridge, MA (USA)-based venture capital firm investing in innovative companies developing novel therapies. The firm has a long track …
Prof. Dr. Roman Jerala, Head of the Department of Synthesis Biology and Immunology at the Chemical Institute, succeeded in obtaining a new project of the European Research Council (ERC), titled CCEdit, to develop the use of the improved CRISPR system for gene knockout in the genome.This is an ERC Proof of Concept (PoC) grant, which is awarded …